334 related articles for article (PubMed ID: 23774673)
21. Specific inhibition of Notch1 signaling enhances the antitumor efficacy of chemotherapy in triple negative breast cancer through reduction of cancer stem cells.
Qiu M; Peng Q; Jiang I; Carroll C; Han G; Rymer I; Lippincott J; Zachwieja J; Gajiwala K; Kraynov E; Thibault S; Stone D; Gao Y; Sofia S; Gallo J; Li G; Yang J; Li K; Wei P
Cancer Lett; 2013 Jan; 328(2):261-70. PubMed ID: 23041621
[TBL] [Abstract][Full Text] [Related]
22. Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia.
Bride KL; Vincent TL; Im SY; Aplenc R; Barrett DM; Carroll WL; Carson R; Dai Y; Devidas M; Dunsmore KP; Fuller T; Glisovic-Aplenc T; Horton TM; Hunger SP; Loh ML; Maude SL; Raetz EA; Winter SS; Grupp SA; Hermiston ML; Wood BL; Teachey DT
Blood; 2018 Mar; 131(9):995-999. PubMed ID: 29305553
[TBL] [Abstract][Full Text] [Related]
23. The relevance of PTEN-AKT in relation to NOTCH1-directed treatment strategies in T-cell acute lymphoblastic leukemia.
Mendes RD; Canté-Barrett K; Pieters R; Meijerink JP
Haematologica; 2016 Sep; 101(9):1010-7. PubMed ID: 27582570
[TBL] [Abstract][Full Text] [Related]
24. The Notch driven long non-coding RNA repertoire in T-cell acute lymphoblastic leukemia.
Durinck K; Wallaert A; Van de Walle I; Van Loocke W; Volders PJ; Vanhauwaert S; Geerdens E; Benoit Y; Van Roy N; Poppe B; Soulier J; Cools J; Mestdagh P; Vandesompele J; Rondou P; Van Vlierberghe P; Taghon T; Speleman F
Haematologica; 2014 Dec; 99(12):1808-16. PubMed ID: 25344525
[TBL] [Abstract][Full Text] [Related]
25. Therapeutic targeting of Notch signaling and immune checkpoint blockade in a spontaneous, genetically heterogeneous mouse model of T-cell acute lymphoblastic leukemia.
Gao J; Van Meter M; Hernandez Lopez S; Chen G; Huang Y; Ren S; Zhao Q; Rojas J; Gurer C; Thurston G; Kuhnert F
Dis Model Mech; 2019 Sep; 12(9):. PubMed ID: 31399482
[TBL] [Abstract][Full Text] [Related]
26. ARRB1-Promoted NOTCH1 Degradation Is Suppressed by OncomiR miR-223 in T-cell Acute Lymphoblastic Leukemia.
Shu Y; Wang Y; Lv WQ; Peng DY; Li J; Zhang H; Jiang GJ; Yang BJ; Liu S; Zhang J; Chen YH; Tang S; Wan KX; Yuan JT; Guo W; Fu G; Qi XK; Liu ZD; Liu HY; Yang C; Zhang LH; Liu FJ; Yu J; Zhang PH; Qu B; Zhao H; He TC; Zou L
Cancer Res; 2020 Mar; 80(5):988-998. PubMed ID: 31822496
[TBL] [Abstract][Full Text] [Related]
27. Bortezomib suppresses the growth of leukemia cells with Notch1 overexpression in vivo and in vitro.
Huang C; Hu X; Wang L; Lü S; Cheng H; Song X; Wang J; Yang J
Cancer Chemother Pharmacol; 2012 Dec; 70(6):801-9. PubMed ID: 22996635
[TBL] [Abstract][Full Text] [Related]
28. NOTCH1 activation clinically antagonizes the unfavorable effect of PTEN inactivation in BFM-treated children with precursor T-cell acute lymphoblastic leukemia.
Bandapalli OR; Zimmermann M; Kox C; Stanulla M; Schrappe M; Ludwig WD; Koehler R; Muckenthaler MU; Kulozik AE
Haematologica; 2013 Jun; 98(6):928-36. PubMed ID: 23349303
[TBL] [Abstract][Full Text] [Related]
29. Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235.
Hall CP; Reynolds CP; Kang MH
Clin Cancer Res; 2016 Feb; 22(3):621-32. PubMed ID: 26080839
[TBL] [Abstract][Full Text] [Related]
30. Synergistic antileukemic therapies in
Sanchez-Martin M; Ambesi-Impiombato A; Qin Y; Herranz D; Bansal M; Girardi T; Paietta E; Tallman MS; Rowe JM; De Keersmaecker K; Califano A; Ferrando AA
Proc Natl Acad Sci U S A; 2017 Feb; 114(8):2006-2011. PubMed ID: 28174276
[TBL] [Abstract][Full Text] [Related]
31. Single-cell RNA-seq reveals developmental plasticity with coexisting oncogenic states and immune evasion programs in ETP-ALL.
Anand P; Guillaumet-Adkins A; Dimitrova V; Yun H; Drier Y; Sotudeh N; Rogers A; Ouseph MM; Nair M; Potdar S; Isenhart R; Kloeber JA; Vijaykumar T; Niu L; Vincent T; Guo G; Frede J; Harris MH; Place AE; Silverman LB; Teachey DT; Lane AA; DeAngelo DJ; Aster JC; Bernstein BE; Lohr JG; Knoechel B
Blood; 2021 May; 137(18):2463-2480. PubMed ID: 33227818
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic potential of Notch inhibition in T-cell acute lymphoblastic leukemia: rationale, caveats and promises.
Sarmento LM; Barata JT
Expert Rev Anticancer Ther; 2011 Sep; 11(9):1403-15. PubMed ID: 21929314
[TBL] [Abstract][Full Text] [Related]
33. DDX5 is a positive regulator of oncogenic NOTCH1 signaling in T cell acute lymphoblastic leukemia.
Lin S; Tian L; Shen H; Gu Y; Li JL; Chen Z; Sun X; You MJ; Wu L
Oncogene; 2013 Oct; 32(40):4845-53. PubMed ID: 23108395
[TBL] [Abstract][Full Text] [Related]
34. Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia.
Real PJ; Tosello V; Palomero T; Castillo M; Hernando E; de Stanchina E; Sulis ML; Barnes K; Sawai C; Homminga I; Meijerink J; Aifantis I; Basso G; Cordon-Cardo C; Ai W; Ferrando A
Nat Med; 2009 Jan; 15(1):50-8. PubMed ID: 19098907
[TBL] [Abstract][Full Text] [Related]
35. Therapeutic targeting of NOTCH1 signaling in T-cell acute lymphoblastic leukemia.
Palomero T; Ferrando A
Clin Lymphoma Myeloma; 2009; 9 Suppl 3(Suppl 3):S205-10. PubMed ID: 19778842
[TBL] [Abstract][Full Text] [Related]
36. Prostaglandin E2 stimulates cAMP signaling and resensitizes human leukemia cells to glucocorticoid-induced cell death.
Roderick JE; Gallagher KM; Murphy LC; O'Connor KW; Tang K; Zhang B; Brehm MA; Greiner DL; Yu J; Zhu LJ; Green MR; Kelliher MA
Blood; 2021 Jan; 137(4):500-512. PubMed ID: 33507291
[TBL] [Abstract][Full Text] [Related]
37. ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia.
Peirs S; Matthijssens F; Goossens S; Van de Walle I; Ruggero K; de Bock CE; Degryse S; Canté-Barrett K; Briot D; Clappier E; Lammens T; De Moerloose B; Benoit Y; Poppe B; Meijerink JP; Cools J; Soulier J; Rabbitts TH; Taghon T; Speleman F; Van Vlierberghe P
Blood; 2014 Dec; 124(25):3738-47. PubMed ID: 25301704
[TBL] [Abstract][Full Text] [Related]
38. Transient responses to NOTCH and TLX1/HOX11 inhibition in T-cell acute lymphoblastic leukemia/lymphoma.
Rakowski LA; Lehotzky EA; Chiang MY
PLoS One; 2011 Feb; 6(2):e16761. PubMed ID: 21326611
[TBL] [Abstract][Full Text] [Related]
39. Leukemia-specific delivery of mutant NOTCH1 targeted therapy.
Roti G; Qi J; Kitara S; Sanchez-Martin M; Saur Conway A; Varca AC; Su A; Wu L; Kung AL; Ferrando AA; Bradner JE; Stegmaier K
J Exp Med; 2018 Jan; 215(1):197-216. PubMed ID: 29158376
[TBL] [Abstract][Full Text] [Related]
40. The NOTCH1/CD44 axis drives pathogenesis in a T cell acute lymphoblastic leukemia model.
García-Peydró M; Fuentes P; Mosquera M; García-León MJ; Alcain J; Rodríguez A; García de Miguel P; Menéndez P; Weijer K; Spits H; Scadden DT; Cuesta-Mateos C; Muñoz-Calleja C; Sánchez-Madrid F; Toribio ML
J Clin Invest; 2018 Jul; 128(7):2802-2818. PubMed ID: 29781813
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
